<DOC>
	<DOCNO>NCT01529008</DOCNO>
	<brief_summary>Non-traumatic osteonecrosis painful disorder hip characterize necrosis osteomedullary tissue , lead subchondral bone collapse joint destruction . Core decompression currently treatment choice early stage osteonecrosis femoral head . This method consist decompress rigid intra-osseous chamber promote revascularization , thus halt progression disease stimulate repair . Still treatment remain highly controversial , since success rate first study repeat . The exact pathology mechanism involve osteonecrosis yet fully elucidate . Several hypothesis evoke , include fat embolism , trabecular bone microfractures , microvascular tamponade , recently , impair bone and/or mesenchymal cell recruitment . Three study indicate potential clinical benefit cell-based approach treatment osteonecrosis ( Hernigou 1997 , Hernigou &amp; Beaujean 2002 , Gangji et al . 2004 ) . This basis observation proprietary population autologous osteoblastic cell ( PREOB® ) develop . This Phase 3 study aim demonstrate efficacy safety PREOB® treatment early stage osteonecrosis femoral head . More specifically , purpose study demonstrate core decompression/PREOB® implantation necrotic lesion superior core decompression/placebo implantation relieve hip symptom halt ( revert ) radiological progression disease .</brief_summary>
	<brief_title>Phase 3 Study Autologous Osteoblastic Cells Implantation Early Stage Osteonecrosis Femoral Head</brief_title>
	<detailed_description />
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>Men woman 18 70 year ( inclusive ) diagnosis ARCO Stage I II nontraumatic osteonecrosis femoral head , confirmed central image analysis base Xray MRI . Ability provide write , date , sign informed consent prior study related procedure understand comply study requirement Diagnosis Osteonecrosis : 1 . ARCO stage I associate WOMAC® VA3.1 pain score ≥20 mm necrotic angle sum ≥190° base sagittal coronal MRI view 2 . ARCO stage II associate WOMAC® VA3.1 pain score ≥20 mm necrotic angle sum &lt; 190° base sagittal coronal MRI view 3 . ARCO stage II associate pain necrotic angle sum ≥190° base sagittal coronal MRI view 4 . Associated corticosteroid and/or alcohol abuse and/or idiopathic Normal haematology function , define leukocyte ≥3000/mm3 , absolute neutrophil count ≥1500/mm3 , platelets ≥140,000/mm3 , haemoglobin concentration ≥10g/dl ( peripheral blood test ) Current symptom and/or sign related disease study Exclusively diaphyseal metaphyseal osteonecrotic lesion Traumatic hyperbaric osteonecrosis , osteonecrosis associate hemoglobinopathy coagulopathy ( e.g. , thalassemia , sickle cell disease , … ) , Gaucher 's disease Osteoarthritis target hip define Kellgrens stage ≥2 , assessed Central Radiologist Patients suffer medical condition interfere patient 's pain evaluation hip evaluation , knee arthritis . Bone fracture bone infection hip evaluation . Patients candidate predictable joint replacement hip evaluate Current previous diagnosis , sign and/or symptom Active hepatitis B ( define positive HBs Ag and/or positive PCR ) , active hepatitis C ( define positive PCR ) , positive serology HIV , Syphilis , HTLV1 Presence , previous history , risk factor disease cause prion , recipient graft cornea , sclera , dura mat History blood loss exceed 450 ml ( incl . donation ) within 1 month screen Renal impairment define estimate creatinine clearance value &lt; 30 ml per min , calculate CockcroftGault formula Hepatic impairment , define alanine aminotransferase aspartate aminotransferase ≥ 3 time upper limit normal Poorly control diabetes mellitus , define HbA1C &gt; 9 % Global sepsis Allergy gentamicin porcine collagen substance device patient might expose context study relate intervention ( i.e. , bone marrow harvest implantation ) , judge Investigator History hypersensitivity human biological material , include blood blood derive product , document clinically laboratory test Current past history solid haematological neoplasia ( except basal cell carcinoma skin carcinoma situ cervix treat evidence recurrence ) History bone marrow transplantation Patients life expectancy le 2 year , judge Investigator Current previous treatment Patients participate another clinical trial within 3 month screen Patients previously treat PREOB® Patients treat core decompression hip evaluation within 6 month screen Treatment dose prednisolone ≥15 mg per day ( equivalent ) within 1 month screening , patient anticipate needs daily corticoid dose ≥15 mg prednisone ( equivalent ) 6 month period follow PREOB/Placebo implantation Illicit drug alcohol abuse interfere patient 's ability understand comply study requirement , judge Investigator Safety aspects concern female patient childbearing potential Pregnancy Breastfeeding Women childbearing potential willing able use reliable contraceptive method least 6 week prior screen whole study period . Reliable contraceptive method include orally administer hormonal contraceptive , surgical intervention ( e.g. , tubal ligation ) , intrauterine device ( IUD ) . Other exclusion criterion : Body Mass Index ( BMI ) ≥ 35 kg/m2 Patients unable undergo MRI , e.g . patient pacemaker , intraocular intracerebral metallic foreign body , mechanical artificial heart valves Patients unable undergo general anaesthesia surgical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Osteonecrosis</keyword>
	<keyword>Femoral Head</keyword>
	<keyword>Hip</keyword>
	<keyword>Orthopedics</keyword>
	<keyword>Bone</keyword>
	<keyword>Musculoskeletal Disorders</keyword>
</DOC>